Results 251 to 260 of about 103,385 (306)

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

open access: yesCancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao   +12 more
wiley   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

open access: yesCancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida   +15 more
wiley   +1 more source

Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

open access: yesCell Proliferation, EarlyView.
Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy.
Qianwen Chen   +5 more
wiley   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng   +6 more
wiley   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer   +10 more
wiley   +1 more source

Recent trends of incidence and mortality of cutaneous lymphomas in Germany

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Primary cutaneous lymphomas (PCL) are primarily composed of cutaneous T‐cell lymphomas (CTCL), followed by cutaneous B‐cell lymphomas (CBCL). This study aimed to assess the incidence and survival rates of PCL in Germany. Methods We analyzed data from the North Rhine‐Westphalia Cancer Registry (2008–2021), which covers a population of
Khodr Cheikh El Najjarine   +4 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot   +3 more
wiley   +1 more source

V-H gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia [PDF]

open access: yes, 2003
Amlot, P   +8 more
core  

ALK Expression in Nerve Sheath Myxoma: A Potential Diagnostic Pitfall

open access: yes
Journal of Cutaneous Pathology, EarlyView.
Daniel Cole   +6 more
wiley   +1 more source

Peripheral T‐cell lymphomas

Hematological Oncology, 2023
AbstractThe treatment of peripheral T‐cell lymphomas is challenging, as they often display a severe prognosis and lack effective treatment strategies. We will try to answer three burning questions: can we differentiate the initial treatment based on the histotype and the clinical presentation of peripheral T‐cell lymphoma patients?
Broccoli A., Zinzani P. L.
openaire   +3 more sources

Home - About - Disclaimer - Privacy